Role of VEGF, CD105, and CD31 in the Prognosis of Colorectal Cancer Cases
- 284 Downloads
Colorectal cancer (CRC) incidence is increasing globally. It is ranked as the second most common cancer in women and the third most in men. Angiogenesis plays a significant role in the development and spread of colorectal cancer. Angiogenesis has been proposed as a prognostic marker in a variety of human neoplasms. In this regard, markers of angiogenic endothelial cells are emerging as targets for cancer therapy.
Aim of the Work
The aim of this study is to evaluate the prognostic impact of tumor angiogenesis assessed by microvessel density (MVD) counting using CD31 and CD105 along with VEGF immunostaining in colorectal cancer patients.
VEGF, CD31, and CD105 expressions were evaluated using immunohistochemical staining in 50 patients with colorectal cancer. The relationship between their expressions and clinicopathological factors and outcome of patients were analyzed.
The VEGF expression (70% of the cases) correlated significantly with larger tumor size, higher grade, and advanced tumor stage (p = 0.006, p < 0.001, p < 0.001), respectively. The mean MVD was 24.2 ± VMD by CD105 (p = 0.10.65 019 for CD105, 19.2 ± 8.41 for CD31, respectively. MVD by CD31 (p = 0.023)) and was significant predictive factors for overall survival. Furthermore, the VEGF expression (p = < 0.001) was a significant predictive factor for DFS. There was a statistically significant association between the recurrence rates with both VEGF and CD105 (p < 0.001) but not significant with CD31.
CRC patients with high VEGF, CD105, and CD31 expression showed poor prognosis. The immunohistochemical markers could be used for stratification of patients into low-risk and high-risk groups.
KeywordsVEGF CD105 CD31 Colorectal cancer
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 3.Bendardaf R, Buhmeida A, Hilska M, et al. VEGF-1expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. Anticancer Res. 2008;28(6B):3865–70.Google Scholar
- 4.Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401–410.Google Scholar
- 7.Chen YB, Wan DS, Zhan YQ, Zhou ZW, Li W, Chen G. Correlation of tumor microvessel density to metastasis and recurrence of rectal cancer. Ai Zheng. 2004;23:1203–6.Google Scholar
- 11.Deliu C, Ciurea P, Neagoe D, et al. Evaluation of Angiogenesis in Colorectal Cancer. Current Health Sciences. 2015;41(2).Google Scholar
- 12.Deliu IC, Neagoe CD, Beznă M, et al. Correlations between endothelial cell markers CD31, CD34 and CD105 in colorectal carcinoma. Rom J Morphol Embryol. 2016;57(3):1025–30.Google Scholar
- 15.Hamilton SR, Vogelstein B, Kudo S, Riboli E, Nakamura S, et al. World Health Organization Classification Of Tumours: Pathology and genetics of tumors of the digestive system. Lyon: IARC Press; 2000. p. 104–143.Google Scholar
- 17.Hashim AF, Al-Janabi AA, Mahdi LH, et al. Vascular endothelial growth factor (VEGF) receptor expression correlates with histologic grade and stage of colorectal cancer. Libyan J Med. 2010;5 https://doi.org/10.3402/ljm.v5i0.5059.
- 19.Jamshidi S, Zargaran M, Baghaei F, et al. An immunohistochemical survey to evaluate the expression of CD105 and CD34 in ameloblastoma and odontogenic keratocyst. J Dent (Shiraz). 2014;15(4):192–8.Google Scholar
- 20.Jung I, Gurzu S, Ranica M, et al. The differences between the endothelial area marked with CD31 and CD105 in colorectal carcinomas by computer-assisted morphometrical analysis. Romanian J Morphol Embryol. 2009;50(2):239–43.Google Scholar
- 25.Mohamed AH, Abd El All SH, Kamel AA, et al. Correlation of Vascular Endothelial Growth Factor Expression and Neovascularization with Colorectal Carcinoma: A Pilot Study .journal of adenocarcinoma. 2016;1(1):5Google Scholar
- 26.Mokhtar N, Gouda I, Adel I. Cancer pathology registry (2003–2004) and time trend analysis. In: Mokhtar N, Gouda I, Adel I, editors. Malignant digestive system tumors. Cairo: NCI, Elshere press; 2007. p. 55–67.Google Scholar
- 27.Nakayama H, Enzan H, Miyazaki E, et al. Differential expression of CD34 in normal colorectal tissue, peritumoral inflammatory tissue, and tumourstroma. J Clin Pathol. 2000;53(8):626–9.Google Scholar
- 29.Redston M. Epithelial neoplasm of the large intestine. In: Odze RD, Goldblum JR, Crawford JM (eds). Surgical pathology of the GI tract, liver, biliary tract, and pancreas. Philadelphia: Saunders; 2004. p. 441–472Google Scholar
- 35.Takahashi N, Kawanishi-Tabata R, Haba A, et al. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res. 2001;7(3):524–32.Google Scholar
- 36.Tien YW, Chang KJ, Jeng M, et al. Tumor angiogenesis and its possible role in intravasation of colorectal epithelial cells. Clin Cancer Res. 2001;7(6):1627–32.Google Scholar
- 38.Wang Y, Yao X, Ge J, et al. Can vascular endothelial growth factor and microvessel density be used as prognostic biomarkers for colorectal cancer? A systematic review and meta-analysis. Sci World J. 2014:102736.Google Scholar
- 40.World Health Organization. International Agency for Research on Cancer. Colorectal Cancer: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. International Agency for Research on Cancer. Available at http://globocan.iarc.fr/Pages/fact_sheets_cance r.aspx. Accessed July 1, 2014.